Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie

Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie

Published 2 weeks ago
Description
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us